Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Polycystic Kidney Disease Pipeline Insight

DelveInsight’s, “Polycystic Kidney Disease – Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Polycystic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Polycystic Kidney Disease Understanding

Polycystic Kidney Disease: Overview

Polycystic Kidney Disease is an inherited disorder in which clusters of cysts develop within kidneys, causing them to enlarge and lose function over time. Cysts are noncancerous round sacs containing fluid. The cysts vary in size, and they can grow very large. PKD cysts can slowly replace much of the kidneys, reducing kidney function and leading to kidney failure. Polycystic kidney disease can also cause cysts to develop in other body parts like liver. PKD varies greatly in its severity, and some complications are preventable.


Symptoms

The symptoms of Polycystic Kidney Disease include:


  • Back or side pain
  • An increase in the size of the abdomen
  • Blood in the urine
  • Frequent bladder or kidney infections
  • High blood pressure
  • Kidney stones
  • Fluttering or pounding in the chest
  • Urinary tract or kidney infections


Diagnosis

Ultrasound is the most reliable, inexpensive and non-invasive way to diagnose Polycystic Kidney Disease. A CT scan (computed tomography scan) and MRI (magnetic resonance imaging) may detect smaller cysts that cannot be found by an ultrasound. MRI is used to measure and monitor volume and growth of kidneys and cysts. Genetic testing is recommended where diagnosis based on imaging tests is uncertain.


Treatment

Treatment of people with the disease focuses on managing symptoms and treating complications. Prompt treatment with antibiotics of a bladder or kidney infection may help. Medication to control pain and a healthy lifestyle with regard to smoking cessation, exercise, weight control and reduced salt intake and drinking lots of plain water throughout the day help in slowing down the progression of disease. In 2018, the FDA approved tolvaptan (brand name Jynarque) as a treatment for ADPKD. Controlling high blood pressure can also delay the progression of the disease and slow further kidney damage.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Polycystic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Polycystic Kidney Disease.
  • In May 2019, Otsuka Pharmaceutical and the Japan Kidney Association, a non-profit organization, have concluded a comprehensive agreement to collaborate in Japan on raising the level of disease awareness and medical care for autosomal dominant polycystic kidney disease (ADPKD), a rare and incurable disease of the kidney.

Polycystic Kidney Disease Emerging Drugs Chapters

This segment of the Polycystic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Polycystic Kidney Disease Emerging Drugs


Bardoxolone methyl: Reata Pharmaceuticals

Bardoxolone methyl is an experimental, oral, once-daily activator of Nrf2, a transcription factor that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The molecule is currently under Phase III study for the treatment of autosomal dominant polycystic kidney disease (ADPKD).


Oxipurinol - XORTX Therapeutics

Oxipurinol (XRx-008) is a xanthine oxidase inhibitor that specifically decreases production of uric acid. Purine xanthine oxidase inhibitors such as Oxypurinol have also exhibited the ability to decrease free oxygen radical production, inflammatory cytokine expression, and fibrosis and in addition have anti-viral properties. It is currently under Phase II/III development program for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Further product details are provided in the report……..

Polycystic Kidney Disease: Therapeutic Assessment

This segment of the report provides insights about the different Polycystic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Polycystic Kidney Disease

There are approx. 22+ key companies which are developing the therapies for Polycystic Kidney Disease. The companies which have their Polycystic Kidney Disease drug candidates in the most advanced stage, i.e. phase III include, Abbott.

Phases

DelveInsight’s report covers around 22+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Polycystic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polycystic Kidney Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Polycystic Kidney Disease therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycystic Kidney Disease drugs.

Polycystic Kidney Disease Report Insights

  • Polycystic Kidney Disease Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Polycystic Kidney Disease Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Polycystic Kidney Disease drugs?
  • How many Polycystic Kidney Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polycystic Kidney Disease?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polycystic Kidney Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Polycystic Kidney Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Polycystic Kidney Disease: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Polycystic Kidney Disease – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Polycystic Kidney Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Polycystic Kidney Disease Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Bardoxolone methyl: Reata Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)

  • Comparative Analysis

GLPG 2737: Galapagos NV

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

RGLS-4326: Regulus Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

  • Comparative Analysis

Lixivaptan: Palladio Biosciences

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Polycystic Kidney Disease Key Companies

Polycystic Kidney Disease Key Products

Polycystic Kidney Disease- Unmet Needs

Polycystic Kidney Disease- Market Drivers and Barriers

Polycystic Kidney Disease- Future Perspectives and Conclusion

Polycystic Kidney Disease Analyst Views

Polycystic Kidney Disease Key Companies

Appendix

List of Table

Table 1: Total Products for Polycystic Kidney Disease

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Polycystic Kidney Disease

Figure 2: Late Stage Products                               

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Abbott

• Reata Pharmaceuticals

• XORTX Therapeutics

• Sanofi Genzyme

• Galapagos NV

• Exelixis

• Symphony Evolution

• Regulus Therapeutics

• Palladio Biosciences

• Eloxx Pharmaceuticals

• Syros Pharmaceuticals

• Amgen

Forward to Friend

Need A Quote